ACRS
Aclaris Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +25.0% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 154.55K | $812,954 | n/a | n/a |
| Q2 2026 | 60 | -2 | 41.91M | $221.50M | +3 | −6 |
| Q1 2026 | 65 | -2 | 41.75M | $156.42M | +5 | −7 |
| Q4 2025 | 67 | +2 | 40.44M | $121.72M | +2 | n/a |
| Q3 2025 | 17 | +1 | 36.82M | $69.96M | +1 | n/a |
| Q2 2025 | 13 | 0 | 38.17M | $54.21M | n/a | n/a |
| Q1 2025 | 10 | 0 | 23.63M | $36.15M | n/a | n/a |
| Q4 2024 | 10 | +2 | 20.49M | $50.82M | +2 | n/a |
| Q3 2024 | 7 | -1 | 10.01M | $11.51M | n/a | −1 |
| Q2 2024 | 8 | n/a | 10.87M | $11.95M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Adage Capital Partners ✦ | 9.63M | New | $23.88M | 0.0% | New | 1 | SEC ↗ |
| 2 | D. E. Shaw & Co. ✦ | 3.29M | -2.3% | $8.17M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 3 | Marshall Wace ✦ | 2.63M | New | $6.53M | 0.0% | New | 1 | SEC ↗ ×2 |
| 4 | Millennium Management ✦ | 1.96M | -34.8% | $4.86M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 5 | Renaissance Technologies ✦ | 850.52K | -38.0% | $2.11M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 6 | Two Sigma Investments ✦ | 839.27K | -7.6% | $2.08M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 7 | Geode Capital Management ✦ (passive) | 789.60K | -6.7% | $1.96M | 0.0% | ▼ Trim | 3 | SEC ↗ ×2 |
| 8 | State Street Global Advisors ✦ (passive) | 319.27K | n/a | $791,802 | 0.0% | n/c | 1 | SEC ↗ |
| 9 | T. Rowe Price ✦ | 123.10K | -11.7% | $306,000 | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 55.35K | -84.8% | $137,261 | 0.0% | ▼ Trim | 3 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Adage Capital Partners | $23.88M | 0.0% |
| Marshall Wace | $6.53M | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 135 holders, 108.23M shares, $397.63M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.